ISRCTN82615441已完成3 期
A multi-centre, randomised, controlled, phase iii study to investigate the safety and efficacy of intravenous infusions of VIT-45 in patients with iron deficiency anaemia secondary to chronic inflammatory bowel disease
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 252
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female, inpatient or outpatient, aged 18 to 80 years (inclusive).
- •2. Have IDA secondary to chronic IBD (Crohn’s disease or ulcerative colitis).
- •3. IDA defined as: - Hb = 110 g/L and at least one of the following:
- •3.1. Serum transferrin saturation (TSAT) < 20%.
- •3.2. Serum ferritin < 100 µg/L
- •Hb concentration was defined for inclusion purposes as the mean of 2 qualifying values drawn on different days during the screening period. These 2 days were no more than 14 days an no less than 5 days before baseline. For eligibility, both values had to be =110 g/L or, if one of the two Hb values was greater than 110 g/L, the average of both Hb values had to be =110 g/L and the difference between the two samples was not >10 g/L. Patients who met all criteria, except the last condition were re-screened (i.e., two further Hb assessments on separate days). Also, patients who were previously screened and failed because of the Hb values being >100 g/L, were eligible for re-screening. (changed according to amendment 3, dated 13 October 2004).
- •4. Required treatment with at least 1000 mg total iron, based on individual assessment of iron deficiency
- •5. Females of child-bearing potential that have had a negative urine pregnancy test at screening and practised an acceptable method of birth control during the study and for up to 1 month after the last dose of the study medication. Acceptable methods of birth control included:
- •5.1. Barrier methods (including male and female condoms)
- •5.2. Diaphragms (cervical caps) with intravaginal spermicide (including jellies, foams and suppositories)
- •5.3. Intra-uterine devices or hormonal contraceptives
- •6. Non child-bearing potential including:
- •6.1. Being surgically sterilised at least 6 months prior to the study
- •6.2. Postmenopausal with no menstrual bleeding for at least 2 years prior to the study
- •7. Fertile males that used adequate contraception during the study
- •8. Demonstrated the ability to understand the requirements of the study, provided written informed consent, abide by the study restrictions, and agreed to undergo the required assessments
排除标准
- •1. Blood transfusion or oral or parenteral iron treatment within 30 days prior to enrolment, or anticipated need for a blood transfusion during the study
- •2. Erythropoietin (EPO) treatment within the 8 weeks prior to enrolment
- •3. Documented hypersensitivity to components of VIT-45
- •4. Other types of anaemia (especially haemolytic, macrocytic, hypoplastic, or sideroblastic anaemia).
- •5. Haemochromatosis or other iron-storage disorders
- •6. Untreated vitamin B12 or folic acid deficiency (deficiency defined as below the NR)
- •7. Allergy to acetylsalicylic acid
- •8. Treatment with an investigational drug within the 30 days prior to enrolment
- •9. History of addiction to drugs or chronic alcohol abuse
- •10. Immunosuppressive therapy causing myelosuppression, or need for surgery. For medications permitted see Section 9.4.8
- •11. Active severe infection or malignancy other than carcinoma in situ of the cervix and non-melanoma skin cancer
- •12. Active or chronic liver or kidney disease. Serum albumin <25 g/L or serum creatinine >20 mg/L
- •13. Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) grade III or IV, or poorly controlled hypertension according to the judgement of the investigator
- •14. Positive for anti-HIV 1 and 2.
- •15. Positive for HbsAg, anti-HCV and evidence for active hepatitis, i.e., abnormal liver function test (LFT) results.
- •16. Pregnant women or nursing mothers.
- •17. Endocrinologic or metabolic disorders that are not controlled.
- •18. Prior use of VIT-45 or prior participation in other studies of VIT-45
研究者
相似试验
已完成
不适用
A phase III multicentre, randomised, controlled, clinical trial to assess the safety and efficacy of injectable paromomycin in patients with visceral leishmaniasis (India)Visceral leishmaniasis (VL)Infections and InfestationsISRCTN68386084ICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)667
已完成
不适用
A randomised study of radiotherapy and concomitant Temodal® (temozolomide) or neoadjuvant chemotherapy followed by radiotherapy and concomitant Temodal® in patients with high grade gliomaGrade III (anaplastic astrocytoma) or grade IV (glioblastoma multiforme) tumoursMalignant neoplasm of brainCancerISRCTN45209900ordic Clinical Brain Tumour Study Group (Sweden)143
进行中（未招募）
不适用
The purpose of the study is to compare and evaluate the generic Brinzolamide ophthalmic suspension with a registered and marketed Brinzolamide ophthalmic suspension as a treatment for ocular hypertension and glaucomaPatients suffering from open angle glaucoma and ocular hypertension with an elevated IOP, higher than 22mmHg and and lower or equal than 35 mmHgEUCTR2011-003692-12-PLAZAD Pharma AG90
已完成
3 期
A study on treatment of COVID-19 patients with study drug along with standard of careCTRI/2020/05/025369Medanta Institute of Education and Research MIER180
进行中（未招募）
1 期
A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who have not experienced disease progression or unacceptable toxicity during chemotherapy. - SATURAdvanced (stage IIIB or IV) NSCLC previously treated with 4 cycles of a platinum-based chemotherapyEUCTR2005-002241-39-GBF. Hoffmann-La Roche Ltd864